Malaysia MDA–HSA Regulatory Reliance 2026
Malaysia’s 2026 MDA–HSA Regulatory Reliance update formally recognizes Singapore’s HSA as a reference authority after a six-month pilot. Devices registered with HSA may qualify for conformity assessment in Malaysia via verification, benefiting from lower CAB fees and shorter review timelines. The programme strengthens ASEAN regulatory convergence and supports faster Malaysia medical device registration while maintaining compliance and safety standards.
Following our previous update on “Malaysia-Singapore 2025 MOU on Medical Device Regulatory Reliance” published on August 25th 2025, Malaysia’s regulatory authority, the Medical Device Authority (MDA), has announced that it will formally recognize Singapore’s Health Sciences Authority (HSA) as a reference country under its Medical Device Regulatory Reliance Programme.
This confirmation follows the successful six-month pilot implementation conducted from 1 September 2025 to 28 February 2026. Under this 2026 update, medical devices already registered in Singapore may now qualify for conformity assessment in Malaysia via a verification process, benefiting from lower Conformity Assessment Body (CAB) fees and typically shorter review timelines.
Key Updates in the 2026 MDA–HSA Reliance Programme
With the pilot phase successfully completed, MDA will now:
Formally recognize HSA as a reference authority
Permit use of Singapore approvals for conformity assessment by verification
Provide a streamlined regulatory pathway for eligible manufacturers
Offer reduced CAB fees
Shorten review timelines in most qualifying cases
This marks the transition of the reliance programme from pilot stage to formal implementation.
Impact on Malaysia Medical Device Registration
Manufacturers holding valid HSA approval may benefit from a more efficient pathway to Malaysia market access.
Key advantages include:
Lower conformity assessment costs
Faster time to approval
Reduced duplication of technical evaluation
Greater regulatory predictability
Through the verification route, Malaysian CABs may leverage prior HSA assessment outcomes, minimizing the need for full reassessment where appropriate.
Manufacturers must still ensure compliance with Malaysia-specific regulatory requirements, including classification rules, labeling obligations, and post-market surveillance responsibilities.
Eligibility and Compliance Considerations
To qualify under the reliance pathway, manufacturers should:
Ensure the device holds valid and active HSA registration.
Confirm classification alignment between Singapore and Malaysia frameworks.
Prepare complete technical documentation for CAB verification.
Coordinate with a Malaysian authorized representative where required.
Final eligibility remains subject to MDA and CAB review.
Regional Regulatory Significance
The formal recognition of HSA as a reference authority demonstrates Malaysia’s growing adoption of regulatory reliance mechanisms. Such frameworks:
Optimize regulatory resources
Reduce redundant assessments
Accelerate patient access to medical devices
Support ASEAN regulatory convergence
This development reinforces Malaysia’s commitment to efficient, risk-based regulatory systems while maintaining safety and quality oversight.
External References
Internal References
Learn more about:
MarketHSA Singapore Medical Device RegistrationMarketMDA Malaysia Medical Device RegistrationResearch ReportContinuous Glucose Monitors: The Global Regulatory MapResearch ReportAI as a Medical Device: The Global Regulatory MapBlog ArticleTurn FDA & EU Approvals Into Global Market AccessResearch ReportMalaysia's Medical Device and IVD MarketVideoHow to Register a Medical Device in MalaysiaVideoHow to Register a Medical Device in SingaporeMarket ServiceHSA Singapore Medical Device Classification and GroupingVideoHow to register a medical device in the PhilippinesLet's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us